# ANI Pharmaceuticals Inc. (ANIP) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $71.23, market value $1.6 billion.

## Valuation
- **P/E (trailing): 15.5×** (5-yr avg 44.3×, 3-yr avg 44.3×). ANI Pharmaceuticals Inc. trades at 15.5× trailing earnings, well below its own five-year average of 44.3×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 6.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.02**. A PEG of 0.02 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.7×**. Each dollar of revenue is priced at 1.7×.
- **Price / book: 2.6×**. The shares trade at 2.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 7.0×**. Enterprise value is 7.0× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 10.6%** (5-yr avg 3.9%). Free cash flow equals 10.6% of the market value, above its five-year average of 3.9%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 6.4%**. The inverse of the P/E: 6.4% of the price is earned each year.

## Profitability
- **Operating margin: 15.4%**. 15.4% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 8.9%**. 8.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 14.5%**. 14.5% on shareholders' equity is solid.
- **Return on invested capital: 21.1%**. Return on all capital, debt included, is 21.1%: comfortably above what that capital costs.
- **Return on assets: 7.5%**. Each dollar of assets produces 7.5% of profit.

## Growth
- **Revenue growth (1 yr): 43.8%** (3-yr 40.8%/yr, 5-yr 33.5%/yr). Revenue grew 43.8% over the last year, against 33.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 419.2%**. Earnings per share rose 419.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.57**. Debt is 0.57 times equity, moderate leverage.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.48**. A Z-score of 2.48 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. ANI Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover ANI Pharmaceuticals Inc.; the consensus is buy, with an average price target of $108.38 (+52% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -25.8%** (YTD -9.8%, 3-mo -12.2%). The shares are down 25.8% over twelve months including dividends.
- **From 52-week high: -28.4%** (1.5% above the low). Trading 28% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 36**. An RSI of 36 is neutral.
- **Beta (1 yr): 0.36** (volatility 31%). Beta of 0.36 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ANIP · Page: https://foliofundamentals.com/stocks/anip

Not investment advice.